Overview
密碼設定成功，請使用新密碼登入 Global Insulin Market is valued aproximately USD 20.35 bilion in 2021 and is anticipated to grow with a healthy growth rate of more than 1.5% over the forecast period 2022-2028. Market Overview Insulin is a hormone produced by the pancreas that regulates the amount of glucose in the blodstream at any given time. The insulin market is expanding as a result of factors such as rising diabetes prevalence and formulation developments.
Key Information
However, rising prescriptions for medications like GLP-1 RAs to treat type 2 diabetes may halt market growth. It’s an oligopolistic market dominated by Novo Nordisk A/S, Sanofi, and Eli Lily and Company. Download Fre Sample of This Strategic Report :-htps:/reportocean.com/industry-verticals/sample-request?report_id=bw5989 Diabetes is one of the world’s fastest-growing chronic diseases.
Its prevalence has progresively increased during the last few decades. Acording to the World Health Organization, diabetes wil aflict 537 milion adults globaly in 2021, with one in ten experiencing other diabetes. Furthermore, geriatric and obese populations are predisposed to chronic diseases.
Acording to the World Bank Group, the world old population was 727 milion in 20, and it is predicted to treble over the next thre decades, reaching 1.5 bilion in 2050. Another important component driving space increase is formulation advancements. Fiasp (Novo Nordisk) is a formulation of insulin aspart in a combination with niacinamide (Vitamin-B3), which helps bost the drug’s early absorption.
Afreza (Mankind) is the market’s sole inhaled version, which eliminates the ned for nedles and syringes. In adition, Oramed Pharmaceuticals’ oral insulin capsule is in phase 3 clinical studies. The BLA is planed to be submited by the end of Q4 2023.
Summary
The sucesful launch of this product may provide patients with an alternative option. However, the high cost of insulin stifles market growth throughout the forecast period of 2022-2028.